{"credit":[{"email":"jsb42@case.edu","name":"Jill S Barnholtz-Sloan","typeEntity":"Person","typeRoles":[]}],"function":[{"operation":[{"term":"Validation","uri":"http://edamontology.org/operation_2428"},{"term":"Incident curve plotting","uri":"http://edamontology.org/operation_3503"},{"term":"Regression analysis","uri":"http://edamontology.org/operation_3659"}]}],"labels":{"topic":[{"term":"Model organisms","uri":"http://edamontology.org/topic_0621"},{"term":"Statistics and probability","uri":"http://edamontology.org/topic_2269"},{"term":"Biomarkers","uri":"http://edamontology.org/topic_3360"}]},"publication":[{"doi":"10.1093/NOAJNL/VDZ007","pmcid":"PMC6777501","pmid":"31608326"}],"summary":{"biotoolsCURIE":"biotools:IDH-wild-type","biotoolsID":"IDH-wild-type","description":"An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.\n\nBackground:In 2016, the World Health Organization reclassified the definition of glioblastoma (GBM), dividing these tumors into isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant GBM, where the vast majority of GBMs are IDH-wild-type. Nomograms are useful tools for individualized estimation of survival. This study aimed to develop and independently validate a nomogram for IDH-wild-type patients with newly diagnosed GBM.\n\n||| CORRECT NAME OF TOOL COULD ALSO BE 'nomogram' (bio.tools/nomogram), 'Nomogram IDH Wildtype GBM H Gittleman', 'OBTS', 'nomogram IDH-wild-type'","homepage":"https://gcioffi.shinyapps.io/Nomogram_For_IDH_Wildtype_GBM_H_Gittleman/","name":"IDH-wild-type"}}